The Pharmacy Times® Heart Failure Resource Center is a comprehensive resource for clinical news and expert insights on treatments that address issues caused by the heart muscle not pumping blood as well as it should.
September 16th 2025
Digitoxin reduces primary composite vs placebo in HFrEF, with no statistically significant effect on individual components of all-cause mortality or first heart failure-related hospitalization.
Daily Medication Pearl: Finerenone (Kerendia)
February 21st 2022Finerenone (Kerendia) is indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease.
Read More
Certain Patients With Heart Failure May Benefit From Stem Cell Therapy
December 1st 2021Stem cell therapy was associated with a reduction of the number of heart attacks, strokes, and death among people with chronic, high-risk, NYHA class 2 or 3 heart failure with reduced ejection fraction (HFrEF), according to a study presented at the American Heart Association’s Scientific Sessions 2021.
Read More